REDWOOD CITY, Calif., Sept. 3, 2014 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Relypsa, Inc. (Nasdaq:RLYP), please note that the conference time listed in the first paragraph should be 3:30 p.m. ET, not 2:55 p.m. ET as originally issued. The corrected text follows:
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that John Orwin, Chief Executive Officer, will present a corporate overview at the Morgan Stanley Global Healthcare Conference on September 9, 2014 at 3:30 p.m. ET.
To access the live webcasts and subsequent archived recordings of these presentations, please visit Relypsa's website at www.relypsa.com.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The company's two-part pivotal Phase 3 trial of its lead product candidate, patiromer, for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood, has been completed and the primary and secondary endpoints were met. Relypsa has global royalty-free commercialization rights to patiromer, which has intellectual property protection in the U.S. until at least 2030. More information is available at www.relypsa.com.
CONTACT: Sylvia Wheeler V.P. Investor Relations and Corporate Affairs 650-421-9504 IR@relypsa.com